Antihypertensive medication and risk of diabetes mellitus

被引:8
作者
Barzilay, Joshua I.
Cutler, Jeffrey A.
Davis, Barry R.
机构
[1] Kaiser Permanente Georgia, Atlanta, GA USA
[2] Emory Univ, Sch Med, Div Endocrinol, Atlanta, GA 30322 USA
[3] NHLBI, Div Cardiovasc Dis, Bethesda, MD 20892 USA
[4] Univ Texas, Sch Publ Hlth, Coordinating Ctr Clin Trials, Houston, TX USA
关键词
angiotensin-converting enzyme inhibitor; angiotensin receptor blocker; elevated glucose; hypertension; thiazide diuretic;
D O I
10.1097/MNH.0b013e328057dea2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Over the past decade post-hoc analyses of clinical trials and observational studies have tended to show that participants treated with thiazide diuretics are at greater risk for newly diagnosed diabetes mellitus than those treated with other medication classes. We review the results of several recent studies on the impact of thiazide-related hyperglycemia and diabetes mellitus on cardiovascular disease outcomes. We also examine the impact of the glucose-sparing effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on preventing cardiovascular disease. Recent findings No consistent or conclusive evidence has been found that hyperglycemia or diabetes mellitus in association with thiazide diuretic use is associated with increased cardiovascular disease outcomes. This benign outcome may be a consequence of the fact that only a segment of such diuretic-associated cases is induced by the usual etiologic mechanisms that are associated with classic 'diabetes mellitus'. Likewise, no evidence has been found that the glucose-lowering effect of angiotensin-converting enzyme inhibitors is associated with decreased cardiovascular disease risk. Summary We conclude that thiazide diuretics are safe to use, even in hypertensive individuals at risk for incident glucose disorders. The use of angiotensin-converting enzyme inhibitors for protection against glucose disorders and subsequent cardiovascular disease remains to be determined.
引用
收藏
页码:256 / 260
页数:5
相关论文
共 27 条
[1]   The effect of antihypertensive agents on new-onset diabetes mellitus: Time to amend the guidelines? [J].
Aksnes T.A. ;
Kjeldsen S.E. ;
Mancia G. .
American Journal of Cardiovascular Drugs, 2006, 6 (3) :139-147
[2]  
[Anonymous], 1989, NEW ENGL J MED, V321, P406
[3]   Antihypertensive drugs and incidence of type 2 diabetes: Evidence and implications for clinical practice [J].
Asfaha, S ;
Padwal, R .
CURRENT HYPERTENSION REPORTS, 2005, 7 (05) :314-322
[4]   Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment - A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [J].
Barzilay, Joshua I. ;
Davis, Barry R. ;
Cutler, Jeffrey A. ;
Pressel, Sara L. ;
Whelton, Paul K. ;
Basile, Jan ;
Margolis, Karen L. ;
Ong, Stephen T. ;
Sadler, Laurie S. ;
Summerson, John .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (20) :2191-2201
[5]  
Bosch J, 2006, NEW ENGL J MED, V355, P1551
[6]   Thiazide-associated glucose abnormalities: Prognosis, etiology, and prevention - Is potassium balance the key? [J].
Cutler, Jeffrey A. .
HYPERTENSION, 2006, 48 (02) :198-200
[7]   Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study [J].
Dunder, K ;
Lind, L ;
Zethelius, B ;
Berglund, L ;
Lithell, H .
BRITISH MEDICAL JOURNAL, 2003, 326 (7391) :681-684
[8]   Differential effects of antihypertensive drugs on new-onset diabetes? [J].
Elliott, WJ .
CURRENT HYPERTENSION REPORTS, 2005, 7 (04) :249-256
[9]   Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial [J].
Gerstein, H. C. ;
Yusuf, S. ;
Holman, R. R. ;
Bosch, J. ;
Anand, S. ;
Avezum, A. ;
Budaj, A. ;
Chiasson, J. ;
Conget, I. ;
Dagenais, G. ;
Davis, M. ;
Diaz, R. ;
Dinccag, N. ;
Enjalbert, M. ;
Escalante, A. ;
Fodor, G. ;
Hanefeld, M. ;
Hedner, T. ;
Jolly, K. ;
Keltai, M. ;
Laakso, M. ;
Lanas, F. ;
Lonn, E. ;
McQueen, M. ;
Mohan, V. ;
Phillips, A. ;
Piegas, L. ;
Pirags, V. ;
Probstfield, J. ;
Shaw, J. ;
Schmid, I. ;
Teo, K. ;
Zimmet, P. ;
Zinman, B. ;
Gerstein, H. C. ;
Yusuf, S. ;
Bosch, J. ;
Pogue, J. ;
Sheridan, P. ;
Dinccag, N. ;
Hanefeld, M. ;
Hoogwerf, B. ;
Laakso, M. ;
Mohan, V. ;
Shaw, J. ;
Zinman, B. ;
Holman, R. R. ;
Diaz, R. ;
Ahuad Guerrero, R. ;
Albisu, J. .
LANCET, 2006, 368 (9541) :1096-1105
[10]   The impart of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes [J].
Gillespie, EL ;
White, CM ;
Kardas, M ;
Lindberg, M ;
Coleman, CI .
DIABETES CARE, 2005, 28 (09) :2261-2266